Evoq Remedies (BOM:543500) Debt-to-EBITDA : 8.64 (As of Sep. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Evoq Remedies Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Evoq Remedies's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was ₹12.76 Mil. Evoq Remedies's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was ₹0.00 Mil. Evoq Remedies's annualized EBITDA for the quarter that ended in Sep. 2023 was ₹1.48 Mil. Evoq Remedies's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 was 8.64.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Evoq Remedies's Debt-to-EBITDA or its related term are showing as below:

BOM:543500' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0 Med: 4.19 Max: 12
Current: 0.62

During the past 5 years, the highest Debt-to-EBITDA Ratio of Evoq Remedies was 12.00. The lowest was 0.00. And the median was 4.19.

BOM:543500's Debt-to-EBITDA is ranked better than
70.67% of 75 companies
in the Medical Distribution industry
Industry Median: 2 vs BOM:543500: 0.62

Evoq Remedies Debt-to-EBITDA Historical Data

The historical data trend for Evoq Remedies's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evoq Remedies Debt-to-EBITDA Chart

Evoq Remedies Annual Data

Trend

Mar19

Mar20

Mar21

Mar22

Mar23

Debt-to-EBITDA

0.08

12.00

5.59

4.19

Evoq Remedies Semi-Annual Data
	Mar19	Mar20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Debt-to-EBITDA	Get a 7-Day Free Trial			-	5.61	17.34	2.42	8.64

Competitive Comparison of Evoq Remedies's Debt-to-EBITDA

For the Medical Distribution subindustry, Evoq Remedies's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Evoq Remedies's Debt-to-EBITDA Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Evoq Remedies's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Evoq Remedies's Debt-to-EBITDA falls into.

Evoq Remedies Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Evoq Remedies's Debt-to-EBITDA for the fiscal year that ended in Mar. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(95.762	+	0)	/	22.884
	=	4.18

Evoq Remedies's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(12.759	+	0)	/	1.476
	=	8.64

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Sep. 2023) EBITDA data.

Evoq Remedies (BOM:543500) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Evoq Remedies Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Evoq Remedies's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Evoq Remedies (BOM:543500) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Evoq Remedies Ltd (BOM:543500) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

Science City Road, A-1106, Empire Business Hub, Near AUDA Water Tank, Sola, Ahmedabad, GJ, IND, 380060

Website

http://www.evoqremedies.com

Evoq Remedies Ltd is engaged in the pharmaceutical business involving marketing, trading and distribution of wide range of pharmaceutical formulation products such as anti-biotic drugs, calcium, multivitamins, injections and others. It operates in a single segment that is Pharmaceutical Trading.

Evoq Remedies (BOM:543500) Headlines

No Headlines